IV golimumab works in kids with polyarticular-course juvenile idiopathic arthritis
Body surface area-based dosing of intravenous (IV) golimumab appears safe and provides pharmacokinetic exposure in paediatric patients with active polyarticular-course juvenile idiopathic arthritis similar to that found in adults with rheumatoid arthritis, according to the results of an open-label study.
